Global Ophthalmology Therapeutics Market Analysis 2017 - 865 Products in Active Development - egulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

Dublin, Nov. 14, 2017 -- The "Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs" drug pipelines has been added to Research and Markets' offering.

The report Frontier Pharma: Ophthalmology Therapeutics Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative.

Ophthalmology pipeline has a highly active deals landscape. There were 271 licensing deals and 152 co-development deals completed between 2006 and 2016 across the therapy area, of which 94 licensing deals and 33 co-development deals had a disclosed value. Many products in the ophthalmology pipeline have previously been involved in licensing and co-development deals. Most of these are in the Preclinical stage of development, although many deals also took place for products at Phase II.

The pipeline contains a diverse range of molecular targets, and no single target dominates by any clear margin. However, products acting on components of the immune system largely cytokines and cytokine receptors and its regulatory signaling pathways make up the largest segment, followed by angiogenesis inhibitors. Generally, the composition by molecular target across the pipeline suggests that product development is shifting away from the type of therapies that currently dominate the market, indicating that the available therapeutic options could diversify.

Scope

• The pipeline is large, with 865 products in active development. Does current pipeline innovation hold the potential to affect the future ophthalmology market?
• There are 194 first-in-class products in the ophthalmologic disorder pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
• Analysis of strategic consolidations and deals revealed a high level of activity in recent years for licensing agreements, but a low level of co-development. How do deal frequency and value compare between molecular targets and molecule types, and which first-in-class targets have not yet been involved in deals?Key Topics Covered:
  

1. List of Tables & Figures

2 Executive Summary
2.1 Market Landscape Poised for Entry of Novel Products
2.2 Moderately Sized but Strong First-in-Class Pipeline
2.3 Strong Uptake of First-in-Class Products in Strategic Consolidations

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Glaucoma
4.1.2 Age-related Macular Degeneration
4.1.3 Diabetic Macular Edema
4.1.4 Diabetic Retinopathy
4.1.5 Dry Eye Syndrome
4.1.6 Inherited Genetic Disorders
4.2 Disease Symptoms
4.3 Epidemiology and Etiology
4.3.1 Glaucoma
4.3.2 Age-Related Macular Degeneration
4.3.3 Diabetic Retinopathy and Diabetic Macular Edema
4.3.4 Dry Eye Syndrome
4.4 Diagnosis
4.5 Pathophysiology
4.5.1 Healthy Eye Physiology
4.5.2 Glaucoma
4.5.3 Age-Related Macular Degeneration
4.5.4 Diabetic Macular Edema and Diabetic Retinopathy
4.5.5 Dry Eye Syndrome
4.5.6 Inherited Genetic Diseases
4.6 Prognosis
4.6.1 Glaucoma
4.6.2 Age-Related Macular Degeneration
4.6.3 Diabetic Retinopathy and Diabetic Macular Edema
4.6.4 Dry Eye Syndrome
4.7 Treatment Options
4.8 Overview of Marketed Products in Ophthalmology
4.8.1 Molecule Type and Target Analysis

5 Assessment of Pipeline Product Innovation
5.1 Ophthalmology Pipeline by Molecular Target
5.2 Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Ophthalmology
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting MER
7.2 Pipeline Programs Targeting Rhodopsin
7.3 Pipeline Programs Targeting NLRP3
7.4 Pipeline Programs Targeting ABCA4
7.5 Pipeline Programs Targeting Complement Factor B
7.6 Pipeline Programs Targeting RPE65 AND RBP4
7.7 Conclusion

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.2.1 Deals by Region, Year and Value
8.2.2 Deals by Stage of Development and Value
8.2.3 Deals by Molecule Type, Mechanism of Action and Value
8.2.4 Table for Licensing Deals Valued Above $100m
8.3 Co-development Deals
8.3.1 Deals by Region, Year and Value
8.3.2 Deals by Stage of Development and Value
8.3.3 Deals by Molecule Type, Mechanism of Action and Value
8.3.4 Table for Co-development Deals Valued Above $100m
8.4 First-in-Class Programs With and Without Prior Deal Involvement

9 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tq8wcm/frontier_pharma

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals, Genomics